Latest Breaking News On - Joshua schafer - Page 1 : comparemela.com

Zevra Therapeutics, Inc (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript

Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.2.

Sumant kulkarniNeil mcfarlaneChristal mickleJonathan aschoffOren livnatLaduane cliftonJoshua schaferNichol ochsnerCorporate communications for zevra therapeuticsDrug enforcement administrationBusiness developmentUnidentified company representativeZevra therapeutics incInnovation mc groupZevra therapeuticsCall transcript march

Zevra Therapeutics (ZVRA) to Acquire Acer Therapeutics (ACER)

Zevra Therapeutics (ZVRA) to Acquire Acer Therapeutics (ACER)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Christal mickleJoshua schaferDanielj manglessJanine bogrisNichol ochsnerHarry palminNick colangeloChris schellingCompany early access programEuropean medicines agencyWilliam blair companyBryan cave leighton paisnerDevelopment officerBusiness development of zevra therapeuticsAcer therapeutics incZevra therapeutics inc

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Chris schellingNick colangeloHarry palminJanine bogrisNichol ochsnerJoshua schaferChristal mickleDanielj manglessBryan cave leighton paisnerCompany early access programWilliam blair companyEuropean medicines agencyCanaccord genuityExchange commissionPillsbury winthrop shaw pittmanAcer therapeutics inc

PHARNEXT: Pharnext convenes its shareholders to approve a new legal and financial framework adapted to its mission

PARIS, France, January 24, 2023 at 8:30 a.m. (CET) - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), a late-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases

France generalUnited statesLawrence steinmanDeborah schwarzFabreguettes leibHugo brugiSukaina virjiJames kuoJoshua schaferMary jane elliottAlexandra harrisonFinancial press relationsRelations internationalEuronext growth stock exchangeConsilium strategic communicationsManagement committee

PHARNEXT: Shareholder Letter: Time to reveal Pharnext true value

PARIS, France, January 11th, 2023, 8:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for rare

United statesFrance generalBaden wübergFabreguettes leibHugo brugiSukaina virjiXavier paoliJames kuoJoshua schaferMary jane elliottRob quinnAlexandra harrisonCompany onEdison investment researchFinancial press relationEuronext growth stock exchange